Author Correction: Senescent cells promote tissue NAD(+) decline during ageing via the activation of CD38(+) macrophages

Plain-language summary

Published 2021 in Nat Metab, this work by Covarrubias AJ and collaborators tackles a specific question within science-focused NMN/NAD+ research.

Key findings reported by the authors

• In vitro / cell culture study in Nat Metab (2021) exploring NAD+ pathway biology
• Cellular-level evidence - does not directly establish human benefit
• Contributes to molecular understanding of NMN/NAD+ effects

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the limited end of the evidence spectrum. Limited-tier evidence (mouse, in-vitro, or single small pilot) is hypothesis-generating only; do not extrapolate dosing or efficacy claims to humans without supporting replication. Findings here are most directly relevant to science decisions. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.